4-1BB-4-1BBL cis-interaction contributes to the survival of self-reactive CD8+ T cell

  • Cell Mol Immunol. 2023 Sep;20(9):1077-1080. doi: 10.1038/s41423-023-01056-3.
Eunjung Cho  #  1  2 ,  Rohit Singh  #  1 ,  Chungyong Han  1  3 ,  Seon-Hee Kim  1  4 ,  Kwang H Kim  2 ,  Bo-Mi Park  5 ,  Dong Hoon Shin  3  6 ,  Seongeun Han  1 ,  Young H Kim  7 ,  Byoung S Kwon  7  8 ,  Ki Taek Nam  9 ,  Beom K Choi  10  11
Affiliations
  • 1. Immuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer Center, Goyang, 10408, Republic of Korea.
  • 2. Severance Biomedical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • 3. Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, 10408, Republic of Korea.
  • 4. Department of Biomedical Laboratory Science, Catholic Kwandong University, Gangneung, 25601, Republic of Korea.
  • 5. Biomedicine Production Branch, Research Institute, National Cancer Center, Goyang, 10408, Republic of Korea.
  • 6. Anticancer Resistance Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, 10408, Republic of Korea.
  • 7. Eutilex Co., Ltd., Geumcheon-gu, Seoul, 08594, Republic of Korea.
  • 8. Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, 70112, USA.
  • 9. Severance Biomedical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea. [email protected].
  • 10. Immuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer Center, Goyang, 10408, Republic of Korea. [email protected].
  • 11. Innobationbio Co., Ltd., Mapo-gu, Seoul, 03929, Republic of Korea. [email protected].
  • # Contributed equally.
PMID: 37365325 DOI: 10.1038/s41423-023-01056-3
Products